The Role of Circulating RBP4 in the Type 2 Diabetes Patients with Kidney Diseases: A Systematic Review and Meta-Analysis
Table 1
Characteristics of included studies.
Author
Year
Country/region
Sample size
Sex (female/total)
Age (year, )
Method
Sample
NOS
DM
Control
DM
Control
Akbay
2010
Turkey
83
28/53
21/31
ELISA
Serum
7
Chang
2008
Taiwan, China
111
54/95
11/16
ELISA
Serum
8
Chu
2011
Taiwan, China
239
22/86
63/153
ELISA
Serum
8
Klisic
2020
Serbia
106
24/40
41/66
ELISA
Serum
7
Mahfouz
2016
Saudi Arabia
200
91/150
35/50
ELISA
Serum
7
Masaki
2008
Japan
58
24/48
NA
NA
ELISA
Plasma
7
Ni
2018
Mainland China
192
69/172
13/20
ELISA
Serum
8
Park
2014
Republic of Korea
689
239/471
41/75
ELISA
Serum
8
Raila
2007
Germany
97
32/62
21/35
NA
49 (21-71)#
ELISA
Plasma
7
Toruner
2011
Turkey
87
22/39
27/48
ELISA
Serum
7
Wang
2013
Mainland China
190
37/120
NA
NA
ELISA
Plasma
6
Xu
2017
Mainland China
1795
303/524
479/763
ELISA
Serum
8
Abbreviations: DM: diabetes mellitus; NOS: Newcastle-Ottawa Scale; ELISA: enzyme-linked immunosorbent assay; NA: not available. Note: DM means DM with CKD, control means DM without CKD. #Data was expressed as median (range).